Sophia Genetics priced a $50 million underwritten public offering of ordinary shares, selling more than 10 million shares at $4.75 each. The offering is expected to close shortly, and the company granted underwriters a 30-day option to buy additional shares. Sophia said it intends to use net proceeds for working capital and general corporate purposes, including expanding the Sophia DDM platform with new features and data modalities. The company also plans to pursue additional collaborations and regulatory clearances/approvals, and may allocate funds to in-license or invest in complementary technologies. The deal underscores investor appetite for precision diagnostic platform builders as companies look to strengthen capabilities and regulatory readiness in a competitive genetic testing landscape.